https://novapharmanews.com/us/news/sls-stock-jumps-biotech-momentum-sellas-gains-2510-percent 2026-06-11T12:26:16.556Z NovaPharmaNews en 2026-06-11T12:19:35.717Z SLS Stock Jumps on Biotech Momentum as SELLAS Gains 25.10% https://novapharmanews.com/uploads/articles/sls-stock-jumps-biotech-momentum-sellas-gains-2510-percent.webp SLS Stock Jumps on Biotech Momentum as SELLAS Gains 25.10% https://novapharmanews.com/us/news/hhs-responds-coolly-to-alcohol-risk-paper-amid-cancer-warning-debate 2026-06-11T12:26:11.629Z NovaPharmaNews en 2026-06-11T12:19:34.040Z HHS responds coolly to alcohol risk paper amid cancer-warning debate liver cancer https://novapharmanews.com/uploads/articles/hhs-responds-coolly-to-alcohol-risk-paper-amid-cancer-warning-debate.webp HHS responds coolly to alcohol risk paper amid cancer-warning debate https://novapharmanews.com/apac/news/blood-pressure-ischemic-stroke-risk-dementia-nationwide-cohort 2026-06-11T12:24:10.194Z NovaPharmaNews en 2026-06-11T12:05:43.419Z Blood pressure and ischemic stroke risk in dementia: nationwide cohort findings ischemic stroke, dementia, hypertension https://novapharmanews.com/uploads/articles/blood-pressure-ischemic-stroke-risk-dementia-nationwide-cohort.webp Blood pressure and ischemic stroke risk in dementia: nationwide cohort findings https://novapharmanews.com/us/news/sepsis-ai-algorithms-need-real-time-data-not-hindsight 2026-06-11T11:34:14.478Z NovaPharmaNews en 2026-06-11T10:07:14.604Z Sepsis AI algorithms need real-time data, not hindsight sepsis https://novapharmanews.com/uploads/articles/sepsis-ai-algorithms-need-real-time-data-not-hindsight.webp Sepsis AI algorithms need real-time data, not hindsight https://novapharmanews.com/eu/news/ema-approves-tx01-pip-unlocking-puma-pathway-theranexus-exeltis 2026-06-11T11:01:24.625Z NovaPharmaNews en 2026-06-11T08:35:44.588Z EMA approves TX01 PIP, unlocking the PUMA pathway for Theranexus and Exeltis TX01 https://novapharmanews.com/uploads/articles/ema-approves-tx01-pip-unlocking-puma-pathway-theranexus-exeltis.webp EMA approves TX01 PIP, unlocking the PUMA pathway for Theranexus and Exeltis https://novapharmanews.com/us/news/fda-approves-first-interchangeable-biosimilars-simponi-simponi-aria 2026-06-11T09:44:35.767Z NovaPharmaNews en 2026-06-11T06:08:45.368Z FDA Approves First Interchangeable Biosimilars to Simponi and Simponi Aria Simponi, Simponi Aria, Immgolis, Immgolis Intri, golimumab, golimumab-sldi, rheumatoid arthritis, ulcerative colitis https://novapharmanews.com/uploads/articles/fda-approves-first-interchangeable-biosimilars-simponi-simponi-aria.webp FDA Approves First Interchangeable Biosimilars to Simponi and Simponi Aria https://novapharmanews.com/us/news/astrazeneca-obesity-push-ultrasound-genetic-medicine-125m 2026-06-11T09:44:37.727Z NovaPharmaNews en 2026-06-11T04:08:10.342Z AstraZeneca expands obesity push as it invests $125M in ultrasound medicine GLP-1, obesity https://novapharmanews.com/uploads/articles/astrazeneca-obesity-push-ultrasound-genetic-medicine-125m.webp AstraZeneca expands obesity push as it invests $125M in ultrasound medicine https://novapharmanews.com/eu/news/chmp-backs-nerandomilast-for-ipf-and-ppf-in-eu 2026-06-11T06:37:50.042Z NovaPharmaNews en 2026-06-11T01:11:36.549Z CHMP backs nerandomilast for IPF and PPF in EU Nerandomilast, Jascayd, idiopathic pulmonary fibrosis, IPF, progressive pulmonary fibrosis, PPF https://novapharmanews.com/uploads/articles/chmp-backs-nerandomilast-for-ipf-and-ppf-in-eu.webp CHMP backs nerandomilast for IPF and PPF in EU https://novapharmanews.com/us/news/fda-drug-approval-what-approval-means-for-pharma-marketing-bd 2026-06-11T04:45:03.925Z NovaPharmaNews en 2026-06-11T01:05:58.154Z FDA Drug Approval: What Approval Means for Pharma Marketing and BD https://novapharmanews.com/uploads/articles/fda-drug-approval-what-approval-means-for-pharma-marketing-bd.webp FDA Drug Approval: What Approval Means for Pharma Marketing and BD https://novapharmanews.com/apac/news/pmda-approves-enhertu-for-her2-low-breast-cancer-in-japan 2026-06-11T10:41:32.545Z NovaPharmaNews en 2026-06-10T22:17:07.203Z PMDA approves ENHERTU for HER2-low breast cancer in Japan